Telix Pharmaceuticals (TLX) Operating Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Operating Leases data on file, last reported at $62.1 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $62.1 million, up 1066.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $62.1 million (up 1066.11% YoY), and the FY2025 annual result was $62.1 million, up 842.35% from the prior year.
• Operating Leases advanced to $62.1 million in Q4 2025 per TLX's latest filing, from $5.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $62.1 million in Q4 2025 and troughed at $5.0 million in Q4 2023.
• A 3-year average of $24.1 million and a median of $5.3 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases climbed 6.53% in 2024, then soared 1066.11% in 2025.
• A 3-year view of Operating Leases shows it stood at $5.0 million in 2023, then rose by 6.53% to $5.3 million in 2024, then soared by 1066.11% to $62.1 million in 2025.
• Business Quant data shows TLX's Operating Leases at $62.1 million in Q4 2025, $5.3 million in Q4 2024, and $5.0 million in Q4 2023.